Loss of Spry1 reduces growth of BRAF(V600)-mutant cutaneous melanoma and improves response to targeted therapy

Mitogen-activated protein kinase (MAPK) pathway activation is a central step in BRAF(V600)-mutant cutaneous melanoma (CM) pathogenesis. In the last years, Spry1 has been frequently described as an upstream regulator of MAPK signaling pathway. However, its specific role in BRAF(V600)-mutant CM is sti...

Descripción completa

Detalles Bibliográficos
Autores principales: Montico, Barbara, Colizzi, Francesca, Giurato, Giorgio, Rizzo, Aurora, Salvati, Annamaria, Baboci, Lorena, Benedetti, Dania, Pivetta, Eliana, Covre, Alessia, Bo, Michele Dal, Weisz, Alessandro, Steffan, Agostino, Maio, Michele, Sigalotti, Luca, Fratta, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244546/
https://www.ncbi.nlm.nih.gov/pubmed/32444628
http://dx.doi.org/10.1038/s41419-020-2585-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244546/
https://www.ncbi.nlm.nih.gov/pubmed/32444628
http://dx.doi.org/10.1038/s41419-020-2585-y

Ejemplares similares